Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.42 |
| ▸ | KDM1B | Q8NB78 | 5/20 | 0.42 |
| ▸ | MAOA | P21397 | 4/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.41 |
| ▸ | DRD3 | P35462 | 6/20 | 0.38 |
| ▸ | HTR6 | P50406 | 5/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21536626 | 0.90 | CYP11B1 (0.44) | KDM1AKDM1BMAOACYP11B1CYP11B2 | |
| SCHEMBL21536693 | 0.75 | DUT (0.41) | DRD3HTR6HRH3KCNH2 | |
| SCHEMBL24153550 | 0.71 | BACE1 (0.33) | DRD2 | |
| SCHEMBL21536692 | 0.69 | HTR6 (0.46) | HTR6 | |
| SCHEMBL20189396 | 0.67 | DUT (0.49) | MAPTSMN1; SMN2 | |
| SCHEMBL21536095 | 0.67 | DUT (0.46) | KDM1ADRD2 | |
| SCHEMBL20189654 | 0.66 | DUT (0.70) | — | |
| SCHEMBL21536743 | 0.65 | DUT (0.47) | — | |
| SCHEMBL21536582 | 0.65 | DUT (0.49) | — | |
| SCHEMBL21536086 | 0.65 | DUT (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168059-B2 | Amino sulfonyl compounds | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168059-B2 | Amino sulfonyl compounds | DPYD, DNPEP, DUT | KDM1A 1148/4885KDM1B 778/4885MAOA 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.